To begin with, we used immunocompetent mice bearing CLDN18.2-positive PANC02 allograft tumor to explore the antitumor activities of FAP-mBBZ CAR-T cells in vivo (Additional file 1: Fig. S3a). This evidence concerns the gene CLDN18 and neoplasm.